Immunosuppression secondary to TNF-α inhibitor therapy is a known risk factor for Listeria infection, 4, 5 although the American Academy of Pediatrics has not yet recommended empiric coverage in patients receiving TNF-α inhibitor therapy. The gene discussed is TNF; the disease is listeriosis.